Framingham-based GTC Biotherapeutics Inc. said its anti-clotting drug ATryn is now commercially available in the United States.
The protein-based treatment is available through GTC’s commercialization partner Lundbeck Inc. of Deerfield, Ill. GTC is due to receive a $1 million payment from Lundbeck for the initial inventory of ATryn.
ATryn is based on a human protein that regulates the body’s blood clotting mechanism. The treatment was developed by GTC in the milk of genetically modified goats. The protein prevents clots in patients at risk for clots during major surgery or childbirth and in patients with a hereditary deficiency of the clot-regulating protein.
ATryn was approved by the U.S. Food and Drug Administration in February.
